Non-muscle invasive bladder cancer: New standards in endoscopic management and adjuvant instillations

**Location:** Room Madrid, North Hall (Level 1)

**Chairs:** M. Babjuk, Prague 5 (CZ)  
M. Brausi, Modena (IT)  
M. Burger, Regensburg (DE)

**Aims and objectives of this session**

Non-muscle invasive bladder cancer (NMIBC) comprises a heterogeneous group in which tumour number, size, grade and pathological stage (pT) are important prognostic factors related to the risk of recurrence, progression and survival. Transurethral resection of bladder tumour (TURBT) is the reference treatment of NMIBC. The accepted standard for “correct” TURBT is complete macroscopic tumour clearance with specimens of the tumour base and resection border sent separately. A key feature of the pathology report is the presence and/or invasion of lamina propria or muscularis propria, the latter being dependent upon the presence of detrusor muscle (DM) in the TURBT specimens. It is now well established that a “correct” TURBT positively influences recurrence and progression. This session aims to provide an overview of new techniques available to improve the quality of TURBT and the deliverance of adjuvant bladder instillations.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**Active surveillance for non-muscle invasive bladder cancer (NMIBC): Result from bladder cancer Italian active surveillance (BIAS) project**

By: Hurle R.¹, Lazzeri M.¹, Saita A.¹, Forni G.¹, Buffi N.¹, Casale P.¹, Lughezzani G.¹, Peschechera R.¹, Pasini L.¹, Zandegiacomo S.¹, Benetti A.¹, Lista G.¹, Maffei D.¹, Cardone P.¹, Colombo P.², Guazzoni G.¹

Institutes: ¹Istituto Clinico Humanitas, Dept. of Urology, Rozzano, Italy, ²Istituto Clinico Humanitas, Dept. of Pathology, Rozzano, Italy

**Can the use of narrow-band imaging (NBI) reduce persistent bladder cancer rate during white-light classic trans-urethral resection of tumor (WLcTURBT)? A preliminary single-center experience in a large case series**

By: Giulianelli R.², Falavolti C.¹, Gentile B.C.², Mirabile G.², Tariciotti P.², Albanesi L.², Buscarini M.³

Institutes: ¹Villa Betania Hospital, Rome, Italy, ²Villa Claudia Clinic, Dept. of Urology, Rome, Italy, ³University Campus Bio-Medico, Dept. of Urology, Rome, Italy

**Monopolar versus bipolar transurethral resection for primary non-muscle invasive bladder cancer**

By: Liem E.¹, McCormack M.², Chan E.³, Matsui Y.⁴, Geavlete P.⁵, Choi Y.⁶, De Reijke T.¹, Farahat Y.¹, Inman B.⁸, De La Rosette J.¹, Naito S.⁹

Institutes: ¹Academic Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ²Centre Hospitalier De L'Universite De Montreal, Dept. of Urology, Montreal, Canada, ³Chinese University of Hong Kong, HKSAR, Dept. of Surgery, Hong Kong, China, ⁴Kyoto University, Dept. of Urology, Kyoto, Japan, ⁵Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania, ⁶Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ⁷Sheikh Khalifa General Hospital, Dept. of Urology, Umm Al Quwain, United Arab Emirates, ⁸Duke University Medical Center, Dept. of Urology, Durham, United States of America, ⁹Harasanshin Hospital, Dept. of Urology, Fukuoka, Japan
658 Transurethral en-bloc hydrodissection for non-muscle invasive bladder cancer: Results of a randomized controlled trial
By: Gakis G.1, Karl A.2, Bertz S.3, Burger M.4, Fritsche H-M.4, Hartmann A.3, Jokisch F.2, Kempenkestenne C.5, Miller K.6, Mundhenck J.6, Schneeevogt B-S.2, Schubert T.1, Schwentner C.6, Wullich B.7, Stenzl A.1
Institutes: 1Eberhard-Karls University, Dept. of Urology, Tübingen, Germany, 2Ludwig-Maximilians University, Dept. of Urology, Munich, Germany, 3Friedrich-Alexander University, Dept. of Pathology, Erlangen, Germany, 4Caritas St. Joseph’s Hospital, University of Regensburg, Dept. of Urology, Regensburg, Germany, 5Charite, University Medicine Berlin, Dept. of Urology, Berlin, Germany, 6Diakonie-Klinikum, Dept. of Urology, Stuttgart, Germany, 7Friedrich-Alexander University, Dept. of Urology, Erlangen, Germany

659 Is restaging transurethral resection (TUR) necessary in patients with non-muscle invasive bladder cancer (NMIBC) and focal lamina propria invasion?
By: Audenet F.1, Retinger C.1, Chien C.2, Benfante N.2, Bochner B.1, Donat M.1, Herr H.1, Dalbagni G.1
Institutes: 1Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 2Memorial Sloan Kettering Cancer Center, Dept. of Biostatistics, New York, United States of America

660 Bladder endoscopic dissection of NMIBC procures better specimens for pathology than standard TURBT - the pathologists’ perspective
By: Daniel G.1, Quintyn-Rant M-L.1, Briere T.2, Roumiguìé M.2, Malavaud B.2
Institutes: 1Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, 2Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France

661 Simultaneous transurethral resection of high grade bladder tumor and benign prostatic hyperplasia (BPH): Oncological safety
By: Sionov B.V., Khunovich D., Benjamin S., Sidi A.A., Tsivian A.
Institutes: E. Wolfson M.C. and The Sackler Faculty of Medicine Tel-Aviv University, Dept. of Urologic Surgery, Holon, Israel

662 Safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I and HIVEC II: An interim analysis of 307 patients
By: Tan W.S.1, Palou J.2, Kelly J.1
Institutes: 1University College Hospitals London, Dept. of Surgery and Interventional Sciences, London, United Kingdom, 2Universitat Autònoma De Barcelona - Fundació Puigvert, Dept. of Urology, Barcelona, Spain

663 Optimal diagnostic performance of photodynamic diagnosis (PDD) and Storz Professional Image Enhancement System (SPIES) is independent from surgeon experience
By: Soria F., Rocardo L.M., Bisano F., Pecoraro A., Filipini C., Zitella A., Gontero P.
Institutes: University of Turin, Città Della Salute E Della Scienza Di Torino, Dept. of Surgical Sciences, Division of Urology, Turin, Italy

664 Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought
Institutes: 1Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 2A.O. Città Della Salute E Della Scienza, University of Turin, Dept. of Urology, Turin, Italy, 3University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 4Paolo Giaccone General Hospital, Dept. of Urology, Palermo, Italy, 5John Radcliffe Hospital, University of Oxford, Dept of Surgical Science, Oxford, United Kingdom, 6Policlinico Tor Vergata-University of Rome, Dept of Urology, Rome, Italy, 7Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept of Urology, Amsterdam, The Netherlands, 8Radboud University Nijmegen Medical Centre, Dept of Urology, Nijmegen, The Netherlands, 9Universit A Vita-Salute. Ospedale S. Raffaele, Dept of Urology, Milan, Italy, 10Motol Hospital,
Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomised controlled trial


Institutes: University College London, Division of Surgery and Interventional Science, London, United Kingdom, University of Birmingham, Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom, University College London Hospitals, Dept. of Urology, London, United Kingdom, James Cook University Hospital, Dept. of Urology, Middlesbrough, United Kingdom, St George's Hospital, Dept. of Urology, London, United Kingdom, Basingstoke and North Hampshire Hospital, Dept. of Urology, London, United Kingdom, Darent Valley Hospital, Dept. of Urology, Dartford, United Kingdom, Queen Elizabeth Hospital, Dept. of Urology, Birmingham, United Kingdom, Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, Withington Hospital, Dept. of Urology, Manchester, United Kingdom, Leicester General Hospital, Dept. of Urology, Leicester, United Kingdom, Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, Queen Alexandra Hospital, Dept. of Urology, Portsmouth, United Kingdom, University Hospital of Wales, Dept. of Urology, Cardiff, United Kingdom

5-year outcomes of RITE thermochemotherapy for BCG unresponsive high risk non muscle invasive bladder cancer

By: Ayres B., Sri D., Perry M., Issa R.

Institutes: St George's Hospital, Dept. of Urology, London, United Kingdom

Comparison of pain, quality of life, lower urinary tract symptoms and sexual function between flexible and rigid cystoscopy in follow-up male patients with non muscle invasive bladder cancer: A randomized controlled cross section single blind study

By: Üçer O., Temeltas G., Yüksel M.B., Gümüş B., Müezzinoğlu Iu T.

Institutes: Celal Bayar University, Faculty of Medicine, Dept. of Urology, Manisa, Turkey

Guidelines update

M. Babjuk, Prague 5 (CZ)